Sausage Recall in 3 States As Listeria Warning Issued
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A Louisiana-based meat processor is recalling around 100 pounds of sausage products because of potential listeria contamination.
Bourgeois Smokehouse, located in Thibodaux, Louisiana, announced the voluntary recall of its ready-to-eat smoked andouille sausage on Tuesday.
The affected items were shipped to Rouses Market retail locations in Alabama, Louisiana and Mississippi.
Newsweek has contacted Bourgeois Smokehouse via email for comment.
Why It Matters
The U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) warns that consumption of food contaminated with listeria can cause listeriosis, an infection that can be particularly serious for certain groups.
Listeriosis can cause fever, muscle aches, headaches, stiff neck, confusion, loss of balance and convulsions, diarrhea and other gastrointestinal symptoms.
In pregnant women, the infection can cause miscarriages, stillbirths, premature delivery or life-threatening infection of the newborn. The infection can also be fatal in older adults and people with weakened immune systems.
A photo of the Bourgeois Smokehouse sausage product that has been recalled.
A photo of the Bourgeois Smokehouse sausage product that has been recalled.
Bourgeois Smokehouse
What To Know
The recall was initiated after a sample of the sausage product tested positive for Listeria monocytogenes during a routine FSIS inspection.
The recalled sausages were produced on May 12, 2025. They do not bear an establishment number or the USDA mark of inspection because they were wrapped and labeled in-store at the time of purchase.
They have been available for purchase at Rouses Market stores in Alabama, Louisiana and Mississippi since May 13.
The FSIS has given the recall a Class I classification, meaning that there is a "reasonable probability that the use of the product will cause serious, adverse health consequences or death."
As of Tuesday, there have been no reports of illness linked to the recalled product.
What People Are Saying
FSIS, said in a January 2024 report on controlling Listeria monocytogenes in ready-to-eat meat and poultry products: "[Ready-to-eat (RTE)] products are of particular concern for contamination with [Listeria monocytogenes (Lm) because they may support the growth of the pathogen during refrigerated storage. In addition, since RTE products are often consumed without further cooking, there is a greater possibility of the occurrence of foodborne illness from these products if they become contaminated."
It added: "Lethality treatments such as cooking meat and poultry products generally eliminate Lm; however, RTE products can be re-contaminated by exposure to the environment after the lethality treatment during peeling, slicing, repackaging, and other processing steps. By controlling sanitation in the post-lethality processing environment or implementing interventions in their products, establishments can ensure that their RTE products do not become contaminated with Lm."
What Happens Next
The FSIS says that anyone experiencing symptoms of listeriosis after consuming these products should seek medical attention. Consumers are advised to check their refrigerators and freezers and discard any products matching the recall details. They can also be returned to the place of purchase. FSIS has encouraged any consumers with questions to contact Bourgeois Smokehouse at 985-447-1604 or bourgeoissmokehouse@comcast.net.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Goliath vs. David: Optum Rx invokes open meetings law to fight Kentucky counties on opioid suits
Tara Hyde, CEO of the Kentucky-based nonprofit People Advocating Recovery, says she has been in recovery for more than a decade from an addiction that began with prescription painkillers. Today she helps others enter recovery and works to reduce stigma around addiction. She wants to see pharmacy benefit managers and other companies held accountable for their role in the overdose crisis. (Sam Foree) UnitedHealth Group's multibillion-dollar pharmacy benefit manager, Optum Rx, is suing five Kentucky counties in an attempt to force them out of national opioid litigation against the company. Pharmacy benefit managers, often called PBMs, act as middlemen that negotiate prescription drug prices between drug companies, insurance plans and pharmacies. Some lawyers and advocates say PBMs helped fuel the overdose crisis by failing to restrict the flow of opioid prescriptions. As governments begin exploring potential lawsuits against PBMs — a step that could represent the next wave in opioid-related litigation — Optum Rx is attempting to shut down those efforts, in some cases before they even fully take shape. In June, Optum Rx sued Anderson, Boyd, Christian, Nicholas, and Oldham counties in Kentucky for allegedly making decisions about participating in the new wave of national opioid lawsuits behind closed doors, violating Kentucky's open meetings law. Optum Rx is asking courts to effectively force those counties to make their decisions again, this time in open meetings, potentially with the hope that some won't bother because of the administrative burden. The result could be fewer claims against the company and possibly less money for it to pay in a future settlement. But legal experts call Optum's case 'hypertechnical' and 'frivolous,' and addiction recovery advocates say it could set a dangerous precedent for companies to evade accountability for their role in fueling the overdose crisis. Christine Minhee — an attorney, national expert on opioid litigation and founder of — said Optum's suit reminded her of an adage among lawyers: 'If the facts are on your side, pound the facts. If the law is on your side, pound the law. If neither is on your side, pound the table.' 'Right now, what we're seeing is it pounding the table,' Minhee said of Optum Rx. The company is 'desperately' trying 'to find some kind of foothold' to get cases against it thrown out. Minhee said these suits fit a pattern of Optum Rx using thin arguments to try to delay or evade opioid litigation nationwide. Last year, Optum Rx, along with another PBM, asked a judge to throw out an opioid lawsuit filed by Los Angeles County, claiming during a December hearing that the county hadn't shown harm. The judge appeared skeptical of the claims and ultimately rejected the companies' request. In April, the same companies tried to oust a federal judge overseeing national opioid litigation, claiming he was biased. Their argument was based partly on a Florida lawyer's having said the judge was 'plaintiff-oriented.' Their attempt failed. Now, Optum Rx is working to keep five Kentucky counties out of that same sweeping opioid litigation. That national legal undertaking began more than seven years ago, as jurisdictions saw overdose deaths climb. Many people who had become addicted to prescription painkillers were cut off by their doctors, and some transitioned to using deadlier heroin or fentanyl. Health care and public safety costs skyrocketed. Thousands of cities, counties, and states began suing health care companies for allegedly creating a public nuisance by aggressively marketing prescription painkillers and negligently distributing them. Those cases were lassoed together into the giant multidistrict litigation, which has resulted in massive settlements. The first few waves of settlements involved opioid manufacturers, distributors and retail pharmacies, with companies such as Johnson & Johnson, CVS and Walgreens agreeing to pay state and local governments billions of dollars. The money is meant to be used for addiction treatment and prevention services — though its rollout has been controversial. To add a new round of companies as defendants, jurisdictions must undertake a multistep process, said Peter Mougey, a Florida-based attorney who represents many local governments in the massive national litigation. The five Kentucky counties in question were in the early stages of that process, only having asked the judge to amend their complaint, he said. They hadn't added Optum Rx yet. If Optum Rx's suits are successful, those counties would have the option of redoing the initial steps of the process in a public meeting, then continuing to add Optum Rx as a defendant, Mougey explained. The company may hope that some counties won't undertake the extra administrative effort. Optum Rx's 'goal is clearly just to wear down and tire out these small counties,' Mougey said. 'They're trying to have a chilling effect on the litigation.' It's not clear why Optum Rx targeted those five counties out of the many localities undertaking the process to add the company as a defendant. The Kentucky counties range from having fewer than 8,000 residents (Nicholas) to more than 70,000 (Christian). One is among the richest in Kentucky (Oldham), while others are poorer. Boyd County, in Appalachia, is one of the hardest hit, with a recent overdose rate twice the state average. Optum Rx, in its filing against Boyd County, which was similar to claims against the other counties, said local authorities had taken official legal action by asking the judge to make a change in its case. The suit said such action must be done in a public meeting and that the county did not hold one. Optum spokesperson Isaac Sorensen told KFF Health News that the company's argument is not about 'a technicality.' It is 'an important legal requirement designed to ensure accountability and transparency before a county takes legal action,' said the statement Sorensen provided. 'We have found many counties ignored this requirement, alongside their duty to preserve relevant evidence, and Optum Rx will defend against these improper legal actions.' The five Kentucky counties disagree with these assertions, according to court records. As of late July, all five had filed motions to dismiss Optum Rx's claim. Boyd County, like the others, argued in its motion to dismiss that asking a judge to amend its complaint was a routine, procedural step that did not require a public meeting. Optum Rx jumped the gun, the county argued, filing a case before any final action had been taken. 'No amended complaint has been filed. No new defendant, OptumRx included, has been added. No new lawsuit has been initiated,' Boyd County's response said. The county also pointed out that it held an open meeting in 2017 that kicked off its involvement in the national litigation and authorized future amendments to that litigation. Hearings on the counties' motions to dismiss Optum Rx's suits are set for late August and early September, according to court records. These cases are shaping up to be a Goliath-versus-David legal action. Although Oldham County is the wealthiest of the Kentucky counties that Optum Rx sued, its most recent budget is less than 0.1% of Optum Rx's annual revenue, which the company reported as exceeding $133 billion in 2024. Oldham County Attorney D. Berry Baxter told KFF Health News he'd seen the impact of the opioid epidemic as a prosecutor working on a growing number of drug-related cases over the years. Now, as settlement money is arriving from other companies, it has funded increased addiction treatment in local jails. More settlement money from additional companies could expand such services, Baxter said. If Optum Rx succeeds in kicking Kentucky counties out of the national litigation, it would set 'a really horrific precedent' for other PBMs and health care companies to do something similar, said Tara Hyde, CEO of the statewide nonprofit People Advocating Recovery. Hyde said she's been in recovery for more than a decade from an addiction that began with prescription painkillers for a broken leg. She wants to see PBMs and other companies held accountable and made to change their processes to prevent future crises. Despite a recent decrease in overdose deaths nationwide, Hyde said people in her state, their families, and the economy are still hurting. 'Recovery doesn't just happen overnight,' she said. 'Without these dollars that have been a direct result of people being misled, mistreated and taken advantage of, we will still be detrimentally impacted.' This story is republished from KFF Health News, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism. Solve the daily Crossword
Yahoo
38 minutes ago
- Yahoo
Happy Belly Food Groups Heal Wellness QSR Announces the Signing of its Second Franchise Agreement for the Province of Quebec
Toronto, Ontario--(Newsfile Corp. - August 19, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands across Canada is pleased to announce that further to its 40-unit area development agreement for the province of Quebec signed on June 18th, 2025, and the announcement of its first signed franchise agreement on August 15th, it is pleased to announce that a second franchise agreement for Heal Wellness has been signed for the province of Quebec. Heal Wellness ("Heal"), a quick-service restaurant ("QSR") specializing in fresh smoothie bowls, açaí bowls, and smoothies. Happy Belly 1 To view an enhanced version of this graphic, please visit: "This latest agreement represents a continued momentum in Heal's national expansion, especially into Quebec and underscores the growing momentum of Happy Belly's portfolio of emerging brands. With the signing of our second franchisee in Quebec, Heal is rapidly solidifying its presence in the province, demonstrating our ability to successfully introduce and scale brands in new markets. Alongside Rosie's Burgers and Yolks Breakfast, this expansion reinforces Happy Belly's proven track record of building and strengthening emerging concepts across Canada, now making meaningful inroads into Quebec," said Sean Black, Chief Executive Officer of Happy Belly."Quebec represents a significant opportunity for Heal, and the addition of a second franchisee underscores the confidence entrepreneurs have in our brand and growth model. Our Quebec-based area developer partners bring deep expertise in launching and supporting brand operations, ensuring Heal's success in the province. This latest franchise agreement demonstrates the scalability of our franchise model and our commitment to building a truly national footprint for Heal Wellness. Our vision remains clear-to establish Heal Wellness as the leading acai bowl and smoothie brand in Canada." Happy Belly 2 To view an enhanced version of this graphic, please visit: "The Happy Belly portfolio has 616 retail locations under contract-spanning projects in development, under construction, or already open-our franchise pipeline is robust. By carefully selecting the right partners and prime real estate, we will maintain momentum and achieve our disciplined growth objectives through 2026. "We are just getting started," said Sean Heal Wellness Heal Wellness was founded with a passion and mission to provide quick, fresh wellness foods that support a busy and active lifestyle. We currently offer a diverse range of smoothie bowls and smoothies. We take pride in meticulously selecting every superfood ingredient on our menu to fuel the body, including acai smoothie bowls, smoothies, and super-seed grain bowls. Our smoothie bowls are crafted with real fruit and enriched with superfoods like acai, pitaya, goji berries, chia seeds, and more. FranchisingFor franchising inquiries please see or contact us at hello@ About Happy Belly Food GroupHappy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company") is a leader in acquiring and scaling emerging food brands across Canada. Happy Belly 3 To view an enhanced version of this graphic, please visit: Sean BlackCo-founder, Chief Executive Officer Shawn MonizCo-founder, Chief Operating Officer FOR FURTHER INFORMATION, PLEASE VISIT:www: or email hello@ you wish to contact us please call: 1-877-589-8805 Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management. Cautionary Note Regarding Forward-Looking Statements All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws. Forward-Looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include the future performance of Happy Belly and her subsidiaries. Forward-Looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the business plans for Happy Belly described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on To view the source version of this press release, please visit 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
an hour ago
- Yahoo
Eight Sleep raises $100M to expand it AI-powered sleep tech
Roughly one in three adults in the U.S. regularly gets insufficient sleep, driving demand for tools that can monitor, analyze, and enhance rest. Eight Sleep, founded in 2014, offers AI-powered sleep tech products that promise to transform your bed into a preventive health device. The New York-based startup announced Tuesday that it raised a fresh $100 million round from investors such as HSG, Valor Equity Partners, Founders Fund, Y Combinator and athletes including Ferrari F1 driver Charles Leclerc, and Zak Brown, who is the CEO of McLaren F1. With this round, Eight Sleep has raised roughly $260 million total, Pitchbook estimates. It previously raised an $86 million Series C in 2021 by investors who assigned it a $500 million post-money valuation. Eight declined to reveal its current valuation. 'If we successfully execute our AI roadmap, launch internationally, and develop condition-specific interventions, achieving unicorn status will naturally follow,' Alexandra Zatarain, co-founder and CMO of Eight Sleep, told TechCrunch. Eight offers smart mattresses that integrate software and AI to track and enhance sleep quality. Its flagship product, Pod, offers features like measuring sleep stages, heart rate, breathing patterns, and movement. Using these insights, it automatically adjusts temperature, elevation, and firmness. It can also detect snoring and automatically elevate the base in response, according to the company. The company has generated more than $500 million in Pod sales, expanded its revenue tenfold since launching the product in 2019, and collected insights from over one billion hours of recorded sleep data, it says. Eight, which employs just over 100 full-time staff, is now expanding beyond the Pod with its Sleep Agent, an AI-driven system that leverages large language models to create thousands of digital twins for each user and predict outcomes, with the goal of optimizing nightly recovery. This approach shifts sleep technology from reactive tracking to proactive, personalized intervention, said Zatarain. The sleep tech market features a range of competitors, from wearable devices such as Oura, Fitbit, and Apple, to medical-focused companies like ResMed, as well as smart mattress and sleep surface makers, including Sleep Number and ChiliSleep. Eight's core differentiator, Autopilot, 'builds a personal blueprint from night one, then adapts continuously, accounting for seasonality, travel, stress, training, illness, or even a bad night before. And it works independently for each side of the bed,' Zatarain said. The startup plans to use the new funding to accelerate its growth in the medical sector, building on the Pod's health-monitoring capabilities. With the introduction of Health Check, the system can monitor cardiovascular and respiratory patterns with up to 99% accuracy without the need for wearable devices, according to the company. 'We're not replacing your doctor, but we are giving you nightly, high-accuracy health monitoring so you can act early if trends shift. Over time, this data can complement medical care,' Zatarain said. Eight's recently launched Hot Flash Mode employs AI-driven cooling to relieve menopause symptoms. It is also working on contactless solutions for sleep apnea. The company is pursuing FDA approval and will utilize the Pod's real-time biometric monitoring to deliver personalized interventions. Eight Sleep currently ships to over 30 countries—including Canada, the UK and EU nations, Australia, Mexico, and the UAE—and is now planning to expand into China. The CMO told TechCrunch that China, as one of the world's largest consumer markets, is seeing a rise in a health-conscious middle class that prioritizes sleep and overall wellness. Regarding sensitive health data, Zatarain said the company complies with each locale's regulations, including for data storage. 'Privacy is foundational. All data is encrypted, never sold, and fully private. We comply with GDPR and CCPA, and unlike many devices, we don't use microphones. Our biometric sensors are embedded in the bed surface — no wearables, no invasiveness, just passive, high-accuracy insights,' Zatarain said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
